Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

Rashad Burgess is the Executive Director for HIV Community Operations at Gilead Sciences. He spoke with Kayla Thompson about importance of screening, health, and more!

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...

Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.